• Immunome issued 4,425,487 common shares to Bristol-Myers Squibb in an unregistered sale tied to a license amendment.
• Consideration included USD 20 million cash; amendment eliminated all milestone, royalty, or other payment obligations to BMS.
• Company committed to file a resale registration statement for the shares by Nov. 16, 2026.
• Shares issued under Securities Act Section 4(a)(2) private placement exemption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-413217), on October 05, 2026, and is solely responsible for the information contained therein.